Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Anastrozole; Letrozole
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms MONARCH 3
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 15 Mar 2024 Planned End Date changed from 31 Dec 2024 to 16 Dec 2024.
- 01 Feb 2024 This study has been completed in Slovakia, according to European Clinical Trials Database record.
- 05 Dec 2023 Results presented in an Eli Lilly and Company media release.